

Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies

Effective July 7, 2023

Certain eligible pharmacies can administer publicly funded COVID-19 vaccines to eligible individuals (see Pharmacy Eligibility below).

The purpose of this Executive Officer (EO) Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies (EO Notice), and the accompanying Frequently Asked Questions (FAQs) document, is to set out the terms and conditions for a participating pharmacy's submission of claims for payment (claims) for administering injectable COVID-19 vaccines to eligible individuals. Each document is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators. Participating pharmacies must comply with all of the terms and conditions set out in the EO Notice and FAQs.

The EO Notice and the accompanying FAQs document are not intended to describe a pharmacy operator's obligations in respect of administering injectable COVID-19 vaccines under applicable legislation, other agreements with the Province of Ontario, or policies of the Ontario College of Pharmacists (OCP). Pharmacy operators with questions about their legal obligations outside of the HNS Subscription Agreement should refer to the applicable legislation, other agreement, or OCP policy as appropriate.

This EO Notice replaces the previous EO Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies that was effective April 6th, 2023.

Pharmacy Eligibility

In order to be eligible to submit claims for administering a publicly funded COVID-19 vaccine, a pharmacy operator (also referred to in this document as a "participating pharmacy") must be selected to participate by the ministry and meet the following requirements:

- Have a valid HNS Subscription Agreement with the ministry

- Have a valid agreement¹ with the ministry respecting COVID-19 vaccine administration and the use of the Provincial COVID-19 vaccine solution (the “COVID-19 Vaccine Agreement”); and
- Be enrolled in the current Universal Influenza Immunization Program (UIIP)².

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice.

Individual Eligibility

The following rules apply to the interpretation of the eligibility criteria in the summary table below for any COVID-19 vaccine doses.

An individual is eligible to receive a publicly funded COVID-19 vaccine if they live, work, or study in Ontario or they are visiting Ontario from another province / territory or another country, and if they meet the applicable eligibility criteria in the table below. For all vaccine doses, when eligibility is defined by age, individuals must be the respective age of eligibility on the day of the vaccine administration.

Residents of long-term care homes, residents of retirement homes, and persons living in other congregate settings (e.g. assisted-living facilities, naturally occurring congregate retirement settings/seniors apartment buildings, congregate settings for people with developmental disabilities, mental health and addictions issues, etc.) who meet the eligibility criteria in the table below are only eligible to receive a pharmacy-administered vaccine dose when pharmacy staff administer the dose at the long-term care home, retirement home or other congregate setting. Staff, support workers, essential caregivers, volunteers and contractors who are working at the long-term care home, retirement home or other congregate settings are also eligible for pharmacy-administered vaccine doses either at the pharmacy or when the pharmacy staff visit the home / congregate setting, provided that they meet the applicable eligibility criteria in the table below. Pharmacies must coordinate any vaccine administration at a long-term care home, retirement home or congregate setting with the local public health unit and the proprietor of the home/setting.

¹ A valid agreement is in respect of a particular pharmacy operator operating at a specific pharmacy location. Where a pharmacy is sold, or where a pharmacy operator relocates, a new COVID-19 Vaccine Agreement is required to reflect the new pharmacy operator or location.

² Enrollment in the UIIP is in respect of a particular pharmacy operator operating at a specific pharmacy location. Where a pharmacy is sold, or where a pharmacy operator relocates, new enrollment in the UIIP is required to reflect the new pharmacy operator or location.

Informed consent is required to administer any COVID-19 vaccine to an eligible individual.

For a primary series the National Advisory Committee on Immunization (NACI) preferentially recommends receipt of bivalent Omicron-containing mRNA COVID-19 vaccines (i.e., Bivalent Pfizer-BioNTech or Bivalent Moderna) to initiate or complete the primary series for all individuals 6 months and older, without contraindications to the vaccine. If a primary series is started with an mRNA monovalent vaccine, a bivalent Omicron-containing mRNA COVID-19 vaccine can be used to complete the series.

Individuals aged 6 months and older who are moderately to severely immunocompromised may benefit from a primary series with bivalent Moderna (25mcg in 6 months-11 years and 50 mcg in those 12 years and older) compared to bivalent Pfizer (10mcg in 5-11 years and 30mcg in those 12 years and older).

For individuals aged 12 to 29 years, the bivalent Pfizer (30mcg) vaccine is preferred due to the lower risk of myocarditis and / or pericarditis; however, administration of the bivalent Moderna (50mcg) may be considered based on individual clinical judgement.

Individuals are recommended to receive the same mRNA vaccine product for all doses in a primary series, using the dose that is correct for the age at the time of appointment.

Individuals who have received COVID-19 vaccines outside of Ontario or Canada should contact their local public health unit to have their COVID-19 immunization record documented in COVAX_{ON}. Pharmacies should refer to the most recent [COVID-19 Vaccine Guidance](#) for information on completing the primary series with different vaccine combinations.

Primary Series Recommendations for Moderately to Severely Immunocompromised Individuals

An extended primary series constitutes administration of an additional dose to complete the primary series and is recommended for certain moderately to severely immunocompromised individuals 6 months of age and older. See the COVID-19 chapter in the [Canadian Immunization Guide: Immunocompromised persons](#) for more information.

An extended primary series of mRNA COVID-19 vaccines is recommended for the following immunocompromised populations eligible for vaccination with the vaccine product authorized for their age group:

- Individuals receiving dialysis (hemodialysis or peritoneal dialysis)

- Individuals receiving active³ treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- HIV with AIDS-defining illness in last 12 months before starting vaccine series, or severe immune compromise with CD4 count <200 cells/uL or CD4 percentage <15%, or without HIV viral suppression
- Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies⁴ (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the [Canadian Immunization Guide](#) for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.

It is recommended that re-vaccination with a repeat COVID-19 vaccine primary series be initiated post-transplantation for hematopoietic stem cell transplant (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy given the loss of immunity following therapy or transplant.⁵

Staying Up to Date⁶:

- For those aged **6 months to 4 years**, means having a completed primary series. Booster doses are not currently recommended for this age group.

³ Active treatment includes patients who have completed treatment within 3 months. Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g., solely hormonal therapy or radiation therapy). See Ontario Health/Cancer Care Ontario's [Frequently Asked Questions](#) for more information.

⁴ Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months

⁵ As per the [Canadian Immunization Guideline](#), HSCT recipients should be viewed as vaccine naïve (i.e. never immunized) and require re-immunization after transplant.

⁶ This definition is based on [NACI recommendations for COVID-19 vaccine booster doses](#), however, is subject to change as the COVID-19 pandemic evolves.

- For those aged **5 years and older**, means completion of the primary series and receipt of the currently recommended booster dose. Individuals 5 years and older should consider delaying receipt of a COVID-19 vaccine booster until Fall 2023.

Booster Dose Recommendations

A booster dose should be offered if at least six months (168 days) have passed since the last dose or confirmed COVID-19 infection⁷. While the recommended interval is at least 6 months, vaccine administrators can use their discretion to decide on administration prior to the 6-month interval, primarily as a result of operational considerations. The closer the timing is to the optimal interval, the better; evidence shows that the antibody response is higher with longer intervals between infection and vaccination and with longer intervals between vaccination doses.

As of July 7th, 2023, individuals aged 5 years and older should consider delaying receipt of a COVID-19 vaccine booster until Fall 2023. Receiving a booster dose in the Fall, as respiratory season commences will maximize protection against COVID-19 when peak circulation of the virus is expected. The decision to receive a booster dose prior to Fall 2023 may be appropriate for certain individuals based on their unique health status and personal situation. Individuals should be encouraged to speak with their health care provider.

Individuals are recommended to receive a bivalent mRNA vaccine for their booster dose(s). Bivalent boosters in authorized age groups are recommended over monovalent boosters. For individuals in authorized age groups who are not able or willing to receive a bivalent Omicron-containing mRNA COVID-19 vaccine, an original monovalent mRNA COVID-19 vaccine may be offered.

For more clinical information on primary and booster doses, dosing intervals, product preferences, special populations, COVID-19 vaccines interchangeability, and adverse reactions refer to the ministry's most recent [COVID-19 Vaccine Guidance](#).

⁷ A confirmed COVID-19 infection is characterized by positive test or after having symptoms post contact with someone who had a positive test (Refer to Table 3 in the ministry's most recent [COVID-19 Vaccine Guidance](#)).

Summary Table⁸ - COVID-19 Vaccines Individual Eligibility Criteria

Note 1:

There is limited supply of Novavax vaccines. Contact your local public health unit to determine how eligible individuals may receive this vaccine. The safety and efficacy of Novavax vaccines have not been established in individuals who are immunocompromised due to disease or treatment. As such, eligible individuals who choose to be immunized with Novavax vaccines should be informed that there is currently limited evidence of these vaccines in this population. Clinicians should use clinical discretion to offer an additional dose for an extended primary series with Novavax to immunocompromised individuals. For additional information, refer to the [COVID-19 Vaccine Guidance](#).

Note 2:

As of March 6, 2023, bivalent Moderna supply is being switched over to the bivalent Moderna BA.4/5 product and the bivalent Moderna BA.1 product will begin to be phased out. Although the indication for use of bivalent Moderna BA.1 as a booster was expanded to those 6 – 17 years on February 17, 2023, Ontario will not order more supply once the current supply has been depleted.

Note 3:

As of June 30, 2023, Janssen COVID-19 vaccines are no longer being used in Ontario Pharmacies should be informed and stay current with the vaccine's official indications in accordance with Health Canada's approved product monograph, including information regarding recommended dosing as per the product monograph. Ontario is funding vaccine doses, based on recommendations of NACI, the Chief Medical Officer of Health and other health experts as noted in the [COVID-19 Vaccine Guidance](#) and guidance from [NACI](#) and the OIAC.

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice and for details of the provincial rollout plan, please visit the [ministry's website](#).

⁸ For more information on COVID-19 vaccines refer to the ministry's most recent [COVID-19 Vaccine Guidance](#).
Administration of COVID-19 Vaccines in Ontario Pharmacies, Ministry of Health

	Age	Vaccine Product	Vaccine Dosing ⁹
PRIMARY SERIES (and re-vaccination ¹⁰)	6 months to 4 years	<p>**Bivalent Moderna preferred for immunocompromised**</p> <p>Moderna Spikevax Bivalent (BA. 4 / 5) 0.10mg/mL (25mcg/0.25mL) blue cap / grey label (DIN 02532352)</p> <p>Moderna Spikevax 0.10mg/mL (25mcg/0.25mL dose) blue cap / purple label (DIN 02527685)</p> <p>Pfizer-BioNTech Comirnaty 3mcg/0.2mL (3mcg/0.2mL dose) maroon cap / maroon label (DIN 02530325) *DILUTE*</p>	<p>Immunocompetent</p> <p>Moderna - 2 doses, 56 days apart</p> <p>Pfizer - 3 doses, 56 days apart</p> <p>Immunocompromised</p> <p>Moderna - 3 doses, 56 days apart</p> <p>Pfizer - 4 doses, 56 days apart</p>
	5 years	<p>** Bivalent Pfizer preferred **</p> <p>Pfizer-BioNTech Comirnaty Bivalent (BA. 4 / 5) 0.05mg/mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02533197) *DILUTE*</p> <p>Pfizer-BioNTech Comirnaty 10mcg/0.2mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02522454) *DILUTE*</p> <p>Moderna Spikevax 0.10mg/mL (25mcg/0.25mL dose) blue cap / purple label (DIN 02527685)</p>	<p>Immunocompetent</p> <p>2 doses, 56 days apart</p>

⁹ For more information on recommended and minimum intervals between doses refer to the ministry's most recent [COVID-19 Vaccine Guidance](#).

¹⁰ Re-vaccination with a new COVID-19 vaccine primary series is recommended following hematopoietic stem cell transplant (HSCT), hematopoietic cell transplant (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy given the loss of immunity following therapy or transplant.

Age	Vaccine Product	Vaccine Dosing ⁹
	Moderna Spikevax Bivalent (BA.4/5) 0.10mg/mL (25mcg/0.25mL) blue cap / grey label (DIN 02532352)	Immunocompromised 3 doses, 56 days apart
6 to 11 years	** Bivalent Pfizer preferred **	Immunocompetent
	Pfizer-BioNTech Comirnaty Bivalent (BA. 4 / 5) 0.05mg/mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02533197) * DILUTE*	2 doses, 56 days apart
	Pfizer-BioNTech Comirnaty 10mcg/0.2mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02522454) * DILUTE*	Immunocompromised
	Moderna Spikevax Bivalent (BA. 4 / 5) 0.10mg/mL (25mcg/0.25mL) blue cap / grey label (DIN 02532352)	3 doses, 56 days apart
12 years and older	Moderna Spikevax 0.10mg/mL (50mcg/0.5mL dose) blue cap / purple label (DIN 02527685)	
	** Bivalent Pfizer preferred **	Immunocompetent
	Pfizer-BioNTech Comirnaty Bivalent 0.1mcg/mL (30mcg/0.3mL dose) grey cap / grey label (DIN 02531461)	2 doses, 56 days apart
	Pfizer-BioNTech Comirnaty 0.1mcg/mL (30mcg/0.3mL dose) grey cap / grey label (DIN 02527863)	Immunocompromised
	Moderna Spikevax Bivalent (BA. 4 / 5) 0.10mg/mL (50mcg/0.5mL) blue cap / grey label (DIN 02532352)	3 doses, 56 days apart

	Age	Vaccine Product	Vaccine Dosing ⁹
		Novavax Nuvaxovid (see Note 1) 5 mcg/0.5mL dose (DIN 02525364)	2 doses, 56 days apart For those not able or willing to receive a Pfizer-BioNTech or Moderna vaccine.
BOOSTER DOSES¹¹	6 months to 4 years	Not eligible for booster doses	
	5 years	<p>** Pfizer bivalent preferred **</p> <p>Pfizer-BioNTech Comirnaty Bivalent (BA. 4 / 5) 0.5mg/mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02533197) <i>*DILUTE*</i></p> <p>Moderna Spikevax Bivalent (BA.4/5) 0.10mg/mL (25mcg/0.25mL) blue cap / grey label (DIN 02532352) (off- label)</p>	<p>Immunocompetent & Immunocompromised</p> <p>1 dose, six months (168 days) after last dose or confirmed SARS-CoV-2 infection</p>
	6 to 11 years	<p>** Pfizer bivalent preferred **</p> <p>Pfizer-BioNTech Comirnaty Bivalent (BA. 4 / 5) 0.05mg/mL (10mcg/0.2mL dose) orange cap / orange label (DIN 02531461) <i>*DILUTE*</i></p> <p>Moderna Spikevax Bivalent (BA. 4 / 5) 0.10mg/mL (25mcg/0.25mL) blue cap / grey label (DIN 02532352)</p>	<p>Immunocompetent & Immunocompromised</p> <p>1 dose, six months (168 days) after last dose or confirmed SARS-CoV-2 infection</p>

¹¹ While bivalent booster doses are preferred, an individual may receive a monovalent booster with informed consent.
Administration of COVID-19 Vaccines in Ontario Pharmacies, Ministry of Health

	Age	Vaccine Product	Vaccine Dosing ⁹
	12 years and older	<p>** Pfizer bivalent preferred for 12 to 17 years; Bivalent preferred for 18 & older **</p> <p>Pfizer-BioNTech Comirnaty Bivalent 0.10mg/mL (30mcg/0.3mL) grey cap / grey label (DIN 02531461)</p> <p>Moderna Spikevax Bivalent (BA.4/5) 0.10mg/mL (50mcg/0.5mL dose) blue cap / grey label (DIN 02532352)</p> <p>Novavax Nuvaxovid (see Note below) 5 mcg/0.5mL dose (DIN 02525364)</p>	<p>Immunocompetent & Immunocompromised</p> <p>1 dose, six months (168 days) after last dose or confirmed SARS-CoV-2 infection</p> <p>For those not able or willing to receive a Pfizer-BioNTech or Moderna vaccine.</p>

Claims for Payment

- There is no cost to eligible patients who receive the COVID-19 vaccine when administered at a pharmacy.
- For each valid claim submitted, a pharmacy will receive \$13.00 as payment for providing the following services:
 - Providing the patient with details of the process and answering any questions related to the vaccination.
 - Obtaining the consent of the patient or their substitute decision-maker prior to vaccine administration
 - Administering the COVID-19 vaccine.
 - Providing the patient with proper monitoring and written vaccine information as well as after-care instructions following vaccine administration.
 - Providing the patient with a written receipt of the vaccination with the pharmacy contact information **after** the vaccine is administered (see Pharmacy Documentation Requirements section below); a pharmacy may wish to issue an electronic receipt as well. (Note: a written receipt can be printed from COVAX_{ON}).
 - Complying with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAX_{ON} under the COVID-19 Vaccine Agreement.

- Pharmacies may access personal protective equipment (PPE) from the ministry's dedicated supply, if needed, to administer the COVID-19 vaccine. The ministry's supply of PPE must ONLY be used to support the activity of pharmacies administering the publicly funded COVID-19 vaccine.
- The table above lists the publicly funded COVID-19 vaccines that are available to pharmacies and are billable, including any restrictions on administering the vaccine (e.g., age groups).

Exclusions and Restrictions

- If a patient does not have a valid Ontario health card number, pharmacy staff can still administer the publicly funded COVID-19 vaccine, provided that the patient provides an alternate identification confirming their name and date of birth. In such cases, pharmacies must use the proxy patient ID: 79999 999 93.
- Administration of non-publicly funded COVID-19 vaccines that are privately purchased by the pharmacy does not qualify for payment.
- Vaccine administration must occur at the location of the participating pharmacy premises, unless otherwise indicated. The pharmacy is permitted to administer publicly funded vaccines supplied by their distributor in a nearby location (e.g., an adjacent pharmacy parking lot) and retirement homes, elderly congregate settings, long-term care homes, or mobile clinic locations as long as they are able to ensure adherence to public safety and relevant Ministry policy / direction (including infection prevention and control measures), the COVID-19 Vaccine Agreement, and any Ontario College of Pharmacist (OCP) standards, policies or guidelines. See the most recent version of the accompanying FAQs for more information.
- The role of pharmacists, pharmacy students, interns or pharmacy technicians administering the COVID-19 vaccine in initiatives led by other authorized organizations that have entered into COVID-19 Vaccine Agreements with the Ministry (e.g., public health units or hospitals that organize mass immunization clinics) that are not billed through the HNS is excluded from this notice.
- A pharmacist's recommendation to a prescriber that a patient should receive a COVID-19 vaccine is not a billable service under the Pharmaceutical Opinion Program.

Billing Procedures – Summary

- Claims for administering the publicly funded COVID-19 vaccine can only be submitted electronically using the HNS (see “Billing Procedures - Detailed” below). No manual paper claims will be accepted unless 3 intervention codes are required in order to process the claim.
- The Part A pharmacist who administers the vaccine or who is overseeing other pharmacy staff administering the vaccine must be identified in the prescriber field on the claim. Each claim must include the Drug Identification Number (DIN) corresponding to the publicly funded COVID-19 vaccine that was administered to the eligible individual (see Summary Table).
- The person submitting the claim must ensure that the eligible individual’s date of birth, Ontario health number and name (as it appears on the health card / document) are included in the claim. Failure to do so – especially for non-Ontario Drug Benefit (ODB) Program recipients – may impact the ability to submit future claims for these individuals.
 - **For eligible individuals without an Ontario health number, pharmacies must use the proxy patient ID: 79999 999 93 (see below for further details).**

Billing Procedures – Detailed

The claim submission follows the usual process (See [Section 5.1](#) of the Ontario Drug Program Reference Manual) for submitting claims in the HNS with the following additional information:

Fields required for all claims for pharmacist administered COVID-19 vaccines

ODB recipients and non-ODB recipients

- Intervention code ‘PS’: (Professional Care Services)
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered (see table above)
- Valid Pharmacist ID
- Professional fee: \$13.00

Additional fields required for non-ODB recipients with an Ontario health number

When submitting a claim for an eligible individual who does not have ODB coverage, submit the following additional information:

- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Patient's Ontario Health number
- Intervention codes:
 - PS: Professional Care Services
 - ML: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Carrier ID: 'S'
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered
- Valid Pharmacist ID

Additional fields required for non-ODB recipients without an Ontario health number

When submitting a claim for an eligible individual who does not have an Ontario health number, submit the following additional information:

- First Name: Patient's first name
- Last Name: Patient's last name
- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Proxy patient ID: 79999 999 93
- Intervention codes:
 - PS: Professional Care Services
 - PB: Name entered is consistent with card
- Valid Pharmacist ID

Payment for epinephrine auto-injector for emergency treatment after administration of the COVID-19 vaccine

If there is an adverse event resulting immediately after pharmacy staff administers a publicly funded COVID-19 vaccine, the ministry will reimburse pharmacies for the acquisition cost of the epinephrine auto-injector up to the total amount reimbursed.

Emergency treatment must take place in the pharmacy or where the vaccine was administered, for example an adjacent pharmacy parking lot, retirement home, long-term care home, other congregate setting, or mobile clinic location, if applicable.

The claim submission process is the same as the one followed for the publicly funded UIIP. Refer to [Section 6.15](#) of the Ontario Drug Program Reference Manual for billing information.

Pharmacy Documentation Requirements

Pharmacies must keep a record of every dose of publicly funded COVID-19 vaccine administered.

Pharmacists shall keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act*, the COVID-19 Vaccine Agreement, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded COVID-19 vaccine must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded pharmacy service provided to the patient, or until 10 years after the day on which the patient reached or would have reached the age of 18 years, whichever is longer.

Overpayments due to inappropriate claim submissions are subject to recovery.

Pharmacy documentation must be maintained in a readily retrievable format and record requirements are:

- Record of name and address of patient.
- Record of patient's Ontario health number or alternate ID with contact information if applicable.
- Record of name of vaccine administered, dose (including half-dosing if applicable), lot number, expiry date, time, date, route and site of administration.
- Record of pharmacy name, pharmacy address and name and signature of individual who administered the vaccine.
- Record of location of administration (inside pharmacy, pharmacy parking lot or within the retirement home, elderly congregate setting, long-term care home or location of a mobile clinic if applicable)
- Evidence of the provision of a written and electronic (if applicable) record (post administration) of the COVID-19 immunization record to the patient, which includes the pharmacy's contact information and date and time for the second scheduled dose at the same pharmacy location. Note: date and time of the second dose may be hand-written on the written record provided to the patient.

- Record of any serious adverse events following immunization that result in the administration of epinephrine, and the circumstances relating to the administration of the substance.
- Records documenting compliance with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAX_{ON} under the COVID-19 Vaccine Agreement. Note: All respective health care providers whether pharmacist, intern, registered pharmacy student, pharmacy technician or other health care provider must identify themselves as the vaccinator in the COVAX_{ON} system and on the vaccine receipt provided to the patient.

Prior EO Notices

Updates relating to this Executive Officer Notice were, prior to April 6, 2023, communicated as two (2) separate EO Notices (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**; Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**) on the effective dates listed below.

EO Notices in 2023				
April 6	March 6			
EO Notices in 2022				
January 13	April 7	July 28	September 12	November 8
February 18	May 2	August 8	September 26	December 21
March 25	July 14	September 1	October 17	
EO Notices in 2021				
March 10	May 11	June 4	September 1	December 2
March 22	May 13	June 14	September 8	December 17
April 1	May 18	June 17	October 1	December 20
April 19	May 21	June 25	October 8	
April 30	May 23	July 5	November 3	
May 6	May 31	August 18	November 25	

Additional Information:

For pharmacy billing:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For COVID-19 vaccine rollout in pharmacy:

Please email the ministry at: OPDPInfoBox@ontario.ca

For Ministry COVID-19 Vaccine-Relevant Information and Planning Resources

Please access this [website](#)

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.